[Form 4] Eli Lilly & Co. Insider Trading Activity

Rhea-AI Filing Summary

Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), reported acquiring 117 shares of common stock on 08/12/2025 under transaction code P. The reported price was $641.182 per share and her direct holdings after the trade were 2,703.055 shares. The Form 4 was filed by one reporting person.

Insights

Securities Analyst

TL;DR Director acquisition of 117 shares at $641.182 increases direct holdings to 2,703.055 shares; transaction appears routine and non-material.

The filing documents a non-derivative acquisition by Gabrielle Sulzberger on 08/12/2025. The transaction is reported under code P with 117 shares acquired at $641.182 per share, raising direct beneficial ownership to 2,703.055 shares. As disclosed, this is a straightforward insider purchase disclosed on Form 4 and does not, by itself, indicate any change in corporate strategy or governance.

Corporate Governance Expert

TL;DR Routine insider purchase by a director; maintains alignment of management/board with shareholder interests but shows no governance changes.

The report shows Gabrielle Sulzberger, identified as a director, increased her direct holding via a reported acquisition. The transaction is recorded on Form 4 and signed by an authorized representative. The disclosure meets Section 16 reporting requirements and reflects ongoing ownership by a board member; no departures, appointments, or material governance events are reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sulzberger Gabrielle

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		P		117	A	$641.182	2,703.055	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Jonathan Groff for Gabrielle Sulzberger, pursuant to authorization on file	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Eli Lilly (LLY)?

The Form 4 was filed by Gabrielle Sulzberger, who is listed as a director of Eli Lilly & Co.

What transaction was reported on the Form 4 for LLY?

The report discloses an acquisition of 117 shares of Eli Lilly common stock reported under transaction code P.

At what price were the LLY shares reported purchased?

The reported price per share was $641.182 according to the Form 4.

How many LLY shares does the reporting person own after the transaction?

Following the reported transaction, the Form 4 shows 2,703.055 shares beneficially owned directly.

When was the transaction dated on the Form 4 for LLY?

The transaction date reported on the Form 4 is 08/12/2025.